Diabetes mellitus risk is increased by prolonged usage of antidepressants (ADs). Although various mechanisms are suggested for their diabetogenic potential, whether a direct effect of ADs on pancreatic b-cells is involved is unclear. We examined this idea for 3 ADs: paroxetine, clomipramine and, with particular emphasis, fluoxetine, on insulin secretion, mitochondrial function, cellular bioenergetics, KATP channel activity, and caspase activity in murine and human cell-line models of pancreatic b-cells. Metabolic assays showed that these ADs decreased the redox, oxidative respiration, and energetic potential of b-cells in a time and concentration dependent manner, even at a concentration of 100 nM, well within the therapeutic window. These effects were related to inhibition of mitochondrial complex I and III. Consistent with impaired mitochondrial function, lactate output was increased and insulin secretion decreased. Neither fluoxetine, antimycin nor rotenone could reactivate KATP channel activity blocked by glucose unlike the mitochondrial uncoupler, FCCP. Chronic, but not acute, AD increased oxidative stress and activated caspases, 3, 8, and 9. A close agreement was found for the rates of oxidative respiration, lactate output and modulation of KATP channel activity in MIN6 cells with those of primary murine cells; data that supports MIN6 as a valid model to study beta-cell bioenergetics. To conclude, paroxetine, clomipramine and fluoxetine were all cytotoxic at therapeutic concentrations on pancreatic beta-cells; an action suggested to arise by inhibition of mitochondrial bioenergetics, oxidative stress and induction of apoptosis. These actions help explain the diabetogenic potential of these ADs in humans.
Antidepressants (ADs) play a key role in treating depression as well as other psychiatric disorders including anxiety and obsessive-compulsive disorders. However, clinical studies indicate that the tricyclic antidepressant (TCA) and serotonin selective reuptake inhibitor (SSRI) classes of AD are particularly associated with increased risks of hyperglycemia and type 2 diabetes mellitus (T2D) (Andersohn et al., 2009; Brown et al., 2008; Derijks et al., 2008; Kivim€ aki et al., 2010; Khoza and Barner, 2011; Lustman et al., 1997; Rubin et al., 2008) . Although weight gain is a common side effect of AD usage (Uguz et al., 2015) and a risk factor for T2D (Andersohn et al., 2009; Kivim€ aki et al., 2010) , when weight is controlled for, ADs still increase T2D risk (Pan et al., 2012; Rubin et al., 2008) .
The effects of ADs on glucose homeostasis have been widely studied in vivo in rodents. The SSRI fluoxetine when administered acutely produces hyperglycemia without hyperinsulinemia (Gomez et al., 2001; Yamada et al., 1999) , actions suggestive of a direct inhibition of insulin secretion. Similar trends are observed with clomipramine, a TCA, which also produces acute hyperglycemia without hyperinsulinemia in rodents (Gomez et al., 2001; Sugimoto et al., 2003) as well as in humans (Lustman et al., 1997) . In murine models, intraperitoneal administration of fluoxetine or clomipramine produces maximal hyperglycemia within the first 30-90 min of injection (Gomez et al., 2001; Sugimoto et al., 2003; Yamada et al., 1999) ; observations that also indicate a direct action of these drugs on the b-cell, an idea further supported by their ability to inhibit insulin secretion from isolated pancreatic b-cells (Antoine et al., 2004; Cataldo et al., 2015) . The mechanism of glucose stimulus-secretion coupling of insulin from the pancreatic b-cell is well understood, with an essential role played by oxidative metabolism of the sugar (Ashcroft et al., 1994; Maechler 2002) . Clearly, any compound that interferes with mitochondrial bioenergetics and oxidative metabolism will impair insulin secretion; for example the mitochondrial Complex I inhibitor rotenone (MacDonald and Fahien, 1990) , Complex III inhibitor antimycin (MacDonald and Fahien, 1990; Meglasson et al., 1987) , F 0 F 1 ATPase inhibitor oligomycin (Orts€ ater et al., 2002) , and protonophore uncoupler FCCP (MacDonald and Fahien, 1990; Orts€ ater et al., 2002) all act to achieve this.
The ADs, amitriptyline, amoxapine, citalopram, clomipramine, and fluoxetine all cause mitochondrial dysfunction in other cell systems ( Chan et al., 2005; Curti et al., 1999; Eto et al., 1985; Souza et al., 1994; Weinbach et al., 1986; Xia et al., 1999) . Where such events can culminate in oxidative stress and induction of apoptosis (Abdel-Razaq et al., 2011; Li et al., 2012) , whether the same is true of pancreatic beta-cells is unknown.
Mitochondria have key roles in the function of many other cell types, in particular those with a high energetic demand, for example sensory cells, neurons, skeletal, and cardiac muscle. Why reports of adverse effects of chronic AD usage only appear for pancreatic b-cell function and not that of other tissue suggests that the mitochondria of the b-cell may be unique in its sensitivity to these classes of drugs. Indeed the predicted side effects of mitochondrial dysfunction in other cell types, whose function depends heavily on this organelle function: impaired vision, hearing loss, cardiac failure, and skeletal muscle weakness, are not normally associated with AD usage (Joint Formulary Committee, 2016) .
Although mitochondria have key roles in many cell types, whether the diabetogenic effect of ADs is indeed mediated by action of these drugs on this organelle in pancreatic beta-cells has not been explored. In this study, the ability of 3 ADs: paroxetine, fluoxetine and clomipramine, with particular emphasis on fluoxetine, to disrupt mitochondrial function, impair bioenergetics, and inhibit insulin secretion of native and cell-line models of murine pancreatic b-cells was investigated. We investigated the metabolic actions of ADs over a concentration range that encompassed both therapeutic (fluoxetine $0.4 to 1.6 mM, paroxetine $0.03 to 0.4 mM, clomipramine $0.3 to 1.3 mM) as well as toxic plasma levels (fluoxetine >3 mM, paroxetine >1 mM, clomipramine >1.3 mM; Reis et al., 2009; Schulz et al., 2012; Winek et al., 2001 ). In addition, we explored both the effect of chronic actions of these drugs in order to mimic their long term usage, as well as their acute actions at higher concentrations in an attempt to mimic overdose and drug-drug interaction situations. Finally, we have also explored the relationship between mitochondrial blockade and modulation of the ATP-sensitive K þ channels, a key signaling pathway that couples glucose metabolism to insulin section (Ashcroft et al., 1994) .
MATERIALS AND METHODS

Cells
Unless stated otherwise, cells of the mouse pancreatic b-cell line MIN6 were employed (Miyazaki et al., 1990) . The MIN6 cell line is a well-established, time honored, model for the study of pancreatic b-cell function (Cataldo et al., 2015; Daunt et al., 2006; Ishihara et al., 1993; Miyazaki et al., 1990 ) . The main advantage of a cell line for pancreatic b-cell research is that it large numbers of phenotypically homogenous cells are available which are devoid of paracrine and neuroendocrine effects that arise from interaction with the other endocrine and neuronal cell types that reside within the pancreatic islet (Ishihara et al., 1993) . Although MIN6 have been reported to contain and secrete other pancreatic endocrine hormones, these cells still remain primarily b-cell in function (Nakashima et al., 2009) . Cells were grown, and the chronic experiments performed, in Dulbecco's modified Eagle's medium (DMEM) which contained 25 mM glucose and was supplemented with: 2 mM L-glutamine, 10% fetal calf serum, 50 mM 2-mercaptoethanol, and 25 mM HEPES. In this study, cells from passage numbers 35-42 were used. Some experiments were repeated with the human pancreatic betacell line, 1.1B4 (McCluskey et al., 2011) . These cells were maintained and handled using the same protocols as for MIN6.
For validation in native tissue, we used b-cells both from and within mouse islets of Langerhans. Pancreatic islets were isolated from the pancreata of male 30-35 g CD1 mice as previously described (Daunt et al., 2006) . Animals were kept under conditions and methods used that complied with local University rules approved by the UK government home office.
Chronic Studies
Measurement of cell viability with MTT. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay relies on cellular reduction of the MTT substrate to produce a blue formazan product. As such it is a facile indicator of cell viability that results from the product of cell number and redox status (Elmorsy et al., 2014) . The MTT assay was employed in accord with the manufacturer's protocol (CellTiter 96 Non-Radioactive Cell Proliferation Assay; Promega, UK). Cells were incubated for 4, 24, 48, or 72 h in the presence of ADs or vehicle. In one set of experiments, this assay was repeated in the presence of 10 mM reduced glutathione (GSH) with a concentration of AD that inhibited MTT reduction by $50% after 24 h incubation (Elmorsy et al., 2014) .
To account for inter-experimental variation between well cell densities, MTT absorbance values are expressed as a percent of that measured for its respective vehicle control (defined as 100%). For all chronic assays, each experiment was performed in triplicate (technical repeat) with the average value considered as a single biological repeat.
Intracellular ATP content. As a direct measure of bioenergetic potential, intracellular ATP was measured as previously described (Elmorsy and Smith, 2015) . Data was corrected for background luminescence by subtraction of the values measured in media alone. ATP levels are represented as a percentage measured in their respective vehicle control.
Insulin secretion. For this and all subsequent chronic AD incubation assays, cells at confluence were washed twice with PBS and incubated for 24 h in DMEM with ADs or vehicle. To maximize effect detection, concentrations of ADs were chosen that inhibited MTT reduction/ATP production by $50% after 24 h incubation.
To measure insulin secretion, the media was removed and the cells washed with PBS. Cells were then incubated for 15 min in serum free DMEM (25 mM glucose) absent of AD. This was removed for insulin assay and the cells measured for total insulin content. Insulin was measured by ELISA (Crystal Chem, Downers Grove, IL, USA) with secretion normalized to total insulin content.
Lactate production. To measure lactate in the chronic experiments the supernatant was collected and assayed by kit in accord with the manufacturer's instructions (Biovision, Mountain View, CA). Lactate production was normalized to cell number, estimated with a hemocytometer, and expressed as a percentage of lactate produced with the vehicle control.
Mitochondrial complex activity. The effect of ADs on MIN6 cells mitochondrial complexes I and III were assessed as previously described (Elmorsy and Smith, 2015) . To maximize event detection, concentrations of ADs were chosen that inhibited MTT reduction/ATP production by $50% after 24 h incubation.
Oxidative stress. The 3,7-dichlorodihydrofluorescein diacetate (DCFDA) assay was used to detect reactive oxygen species (ROS) and was performed following the protocol of Elmorsy et al (2014) . For a positive control, 1 mM Antimycin A was added for 30 min, this blocks Complex III and generates of ROS. Nonstained cells were used for the blank and were subtracted from the data to correct for background luminescence.
Caspase activity. To determine if the ADs, may induce apoptosis we evaluated the activities of caspases 3, 8, and 9 after treatment with the ADs for 24 h. These were determined using a BD ApoAlert caspase fluorescent assay kits (Clontech Laboratories, Palo Alto, CA).
Acute studies. Unless stated otherwise, acute experiments were performed in a HEPES-buffered Hanks solution which contained (in mM): 138 NaCl, 4.2 NaHCO 3 , 1.2 NaH 2 PO 4 , 5.6 KCl, 1.2 MgCl 2 , 2.6 CaCl 2 , 10 HEPES (pH 7.4 with NaOH), and 0.01% fatty acid free BSA.
Mitochondrial respiratory rate: O 2 consumption. The rate of O 2 consumption (OCR) of MIN6 and 1.1B4 cell suspensions were measured polarographically with a redox over potential of À0.625 V using Clark Oxygen Electrodes (Rank Brothers, Bottisham, UK) as described previously (Daunt et al., 2006) . The background O 2 consumption by the electrode was corrected for by subtraction of the OCR measured after the addition of 6 mM Na azide which blocks Complex IV and mitochondrial respiration. Results obtained with the N,N,N 0 ,N 0 -tetramethyl-p-phenylenediamine (TMPD) and ascorbate electron shuttle system (ASB; Daunt et al., 2006; Duchen et al., 1993) were corrected for autoxidation of ascorbate via subtraction of the OCR obtained with ascorbate in the absence of cells: (0.3 nmol min À1 in 1 ml chamber volume).
To improve the statistical power for the substrate experiments, data was pooled from both control, and AD experiments, which resulted in different n numbers as indicated.
Real time lactate production. Patch-clamp studies of K ATP channel activity. As an indicator of submembrane ATP concentrations K ATP channel activity was measured the with cell-attached patch-clamp technique as previously described (Ashcroft et al. 1988; Smith et al., 2001) . Cells were bathed in a high potassium solution, nominally Ca 2þ free, to electrochemically clamp the cell membrane potential (V m ) to 0 mV. The pipette potential, Vp, was held at þ 70 mV to clamp the transpatch membrane potential to À70 mV: (V m -V p ). The pipette solution contained (in mM): 140 KCl, CaCl 2 2.6, MgCl 2 1.2, and HEPES 10 (pH 7.4 with NaOH). 100 mM tetraethyl ammonium was added to block voltage-gated K þ channels. Patch pipettes, resistances between 2 and 4 MX, were drawn from GC150TF capillary glass (Harvard Instruments), coated with dental wax (Kerr) and fire polished before use. Currents were measured using an Axopatch 1D patch clamp amplifier (Molecular Devices). The zero-current potential of the pipette was adjusted with the pipette in the bath just before seal establishment. No corrections have been made for liquid junction potentials (<4 mV). Currents were low pass filtered at 2 kHz (-3 dB, 8 pole Bessel) and digitized at 10 kHz using PClamp 9.3 (Axon Instruments, Foster City, USA). Single-channel data were analyzed with half-amplitude threshold techniques as implemented in Clampfit Ver. 10.6 (Axon Instruments, Foster City, USA). Channel activity, NPo, was recorded for 3 min periods. These experiments were performed at 21-23 C a temperature at which glucose metabolism (Dawson et al., 1986) and its ability to block KATP channels activity (Ashcroft et al., 1988; Smith et al., 2001) in beta-cells is maintained, albeit slower than at 37 C.
Mitochondrial superoxide
To measure mitochondrial ROS and oxidative stress after acute AD incubation the fluorescent dye MitoSOX was employed in accord with the manufacturer's instructions (ThermoFisher Scientific, Waltham MA USA). Cells cultured in 6-well plates to confluence were incubated in the dark with 5 mM MitoSOX reagent for 10 min at 37 C. Cells were then washed 3 times with PBS and incubated in Hanks solution with drugs for 120 min at 37 C. DMSO was used as the vehicle control, 1 mM antimycin A as the positive control and unstained cells for blank. Cells were then washed again with PBS and the dye excited at 510 nm. The emission at 580 nm was captured by fluorescence microscopy. After subtraction of the blank, the mean value of 5 random images from each well was taken as single sample. Velocity software (Ver. 6.3.1.0, Perkin Elmer Inc.) was used to analyze the fluorescent intensity of individual cells and clusters.
Statistical analysis
Statistical analysis and curve fitting was performed using Graphpad PRISM version 7.01 (San Diego, California USA). Data distributions were tested for normality with the D'Agostino & Pearson omnibus normality test and the appropriate statistical test used as given in the text. Inter-experimental variations within the assay are either indicated by plots of raw values or the coefficient of variation, CV. The concentration-response relationships for the actions of ADs were quantified by fitting the assay data with Equation (1):
Where Y is the % of control (taken as 100%), pedestal is the minimum value for Y, h is the slope index, [AD] is the concentration of antidepressant and IC 50 the concentration of drug that produces half-maximal inhibition. All the data generated was confirmed to best fit with a single rather than a 2 site binding model by the comparison method of Akaike's Information Criteria (Graphpad PRISM).
The relationship between incubation time and IC 50 was quantified by fitting the data with the empirical Equation (2):
Where IC 50 , t is IC 50 at time t in hours, IC 50 , t ¼ 0 is the IC 50 at time 0, plateau is the asymptotic value of IC 50 and K is the rate constant (h À1 ). For the majority of the acute fluoxetine studies its IC 50 , t ¼ 0 value was used: 30 mM. Data are given in text as the mean 6 SEM or median with 5-95% confidence intervals (C.I.), with n the number of individual determinations as appropriate. Statistical significance is defined as p < .05. In graphics, p < .05 is flagged as *, p < .01 as **, p < .001 as *** and p < .0001 as ****. Statistical tests are stated in the text and figure legends where appropriate.
RESULTS
Chronic Studies
The ability of MIN6 to reduce MTT was maintained up to 72 h, the longest period used ( Figure 1A ); in control cells there was no change in MTT reduction with time (Pearson r ¼ 0.79, À0.71 to 1 95% C.I; p ¼ .21), indicative of little cell replication over this time frame. Inter-experimental variation was small and ranged between 2.2 and 4.7% (n ¼ 9). Figure 1B -D illustrates that paroxetine, fluoxetine, and clomipramine inhibited the ability of MIN6 to reduce MTT in a time and concentration manner. Equation (1) was best fit to the data with IC 50 and pedestal values given in Figure 1E and F (h $ 0.5). The maximum amount of block, as indicated by the decrease in pedestal, significantly increased with incubation time for both paroxetine (F test, p < .005) and clomipramine (F test, p < .0001) but not fluoxetine ( Figure 1F ). Only the IC 50 value for fluoxetine showed a significant change in magnitude with time of incubation (F test, p < .0001; Figure  1E ) and was described by Equation (2) with an IC 50, t ¼ 0 of 33 mM (12-53, 95% C.I.), a plateau of 4.7 mM (0-9.5, 95% C.I.), and a K of 0.1 h À1 (0-2.8, 95% C.I.). Figure 1G demonstrates that a significant block of MTT reduction occurred with all 3 ADs at 100 nM, the lowest concentration used (One sample t test relative to vehicle control) at all incubation times. Figure 1H illustrates that co-incubation with 10 mM GSH partially reversed the inhibition of MTT reduction produced by the ADs. Figure 2 shows that intracellular ATP production, like MTT reduction, was inhibited in a concentration-dependent manner after 24-h exposure to AD. Inter-experimental variation ranged from 1.7% CV for control up to 1.8% CV in the presence of fluoxetine (n ¼ 9). Equation (1) was readily fit to the data with the same IC 50 's given in Figure 2D . For each AD tested no significant difference (ANOVA) was found between the IC 50 for MTT and ATP; data when combined with the fact that cell density ( Figure 3F ) did not change suggests that MTT is measuring redox status and not viability. All 3 ADs decreased the activity of both complex I and III (Figure 2E and D; One sample t test relative to control). Inter-experimental variation as indicated by the CV ranged from 5% for control up to 18% for Complex III in the presence of clomipramine (n ¼ 3).
Since these ADs decreased the activities of Complexes I and III, and also impaired the ability of MIN6 cells to reduce MTT and produce ATP, we investigated whether the drugs could affect glycolysis via measurement of their lactate output as well as generate ROS. Figure 3A and B illustrate that paroxetine, fluoxetine, and clomipramine all significantly increased lactate output and ROS when normalized to their respective controls (One sample t-test relative to 100%). However, a slightly different picture was observed when inter-plate variability was not controlled for and raw data was used instead ( Figure 3C and D), with significant effects only observed for fluoxetine when compared to its respective control (ANOVA with Dunnett's).
A prior 24-h incubation in paroxetine and fluoxetine, at concentrations estimated to produce $50% inhibition of MTT reduction/ATP production, significantly decreased the ability of the MIN6 cells to secrete insulin ( Figure 3E , One sample t-test relative to control: 100%), however this treatment did not affect cell density ( Figure 3F ). Similar conditions significantly increased the activity of caspases 3, 8, and 9 ( Figure 3G ).
Acute Studies
As it is not readily possible to measure cellular redox potential via MTT reduction or cellular bioenergetics via ATP production over incubation times of minutes, these parameters were monitored instead by the rate of respiration (OCR) and mitochondrial membrane potential, Dwmit, respectively (Duchen et al., 1993) . Acute actions of these drugs are in keeping with accidental drug overdose, loading dosage, or short term drug-drug interactions.
MIN6 suspensions consumed O 2 (OCR) at a rate commensurate with cell density at 1.3 6 0.7 nmol 10 6 cells À1 min
À1
(n ¼ 112). Addition of 10 mM glucose produced a $1.4-fold increase in OCR to 1.7 6 0.8 nmol 10 6 cells À1 min À1 (n ¼ 112), subsequent addition of fluoxetine significantly decreased OCR ( Figure 4A and C). This effect was concentration-dependent with an IC 50 of 230 mM (139-397, 95% C.I.) and h of 1.1 (0.6-1.6, 95% C.I; Figure 4B ). After 10 min incubation, 3 mM was the lowest concentration of fluoxetine to have a significant effect on OCR (Kruskal-Wallis, Dunn's multiple comparison test). Similar observations were made in the human beta-cell line 1.1B4 with an IC 50 for fluoxetine of 232 mM (53-102, 95% C.I.) and h of 0.8 (0.4-1.2, 95% C.I; Figure 4B ). The apparent potency of fluoxetine to inhibit OCR in MIN6 was increased in 100 nM FCCP (F-test, p < .04; Figure 4C ), with an IC 50 of 97 mM (81-117, 95% C.I.) and h of 1.9 (0.9-2.8, 95% C.I; data not shown). Acutely applied paroxetine failed to affect OCR even up to 100 mM, the highest Data are mean 6 SD as a percentage of values measured under control conditions (n ¼ 9 in all cases). Solid lines are fits of Equation (1) to the data with the parameter values given in (E) and (F). E-F, Time courses of IC50 and pedestal respectively for the inhibition of MTT reduction by the drugs indicated: •, PAR, paroxetine; , FLX, fluoxetine; ᭡, CLM, clomipramine. For E, data is given as mean 6 95% C.I., for F, data is mean 6 SEM (n ¼ 9). Solid line in E is a fit of Equation (2) concentration tested (data not shown) whereas clomipramine inhibited OCR with an IC 50 of 284 mM (319-372, 95% C.I.) and h of 1.5 (0.87-2, 95% C.I) with 30 mM the lowest concentration that had a significant effect after 10-min incubation (Kruskal-Wallis, Dunn's multiple comparison test; data not shown).
To confirm that the acute effect of fluoxetine on O 2 consumption was not unique to cell lines, its effect on mouse pancreatic islets was tested. In the absence of exogenous substrate, pancreatic islets consumed O 2 at 1.9 6 0.5 pmol O 2 islet À1 min
(n ¼ 6). The addition of 20 mM glucose significantly increased OCR $1.6-fold to 3.0 6 0.4 pmol O 2 islet À1 min À1 (p < .05; ANOVA, Sidaks's multiple comparison test; Figure 4D ); values akin to those previously reported (Daunt et al., 2006) . Incubation in 100 mM fluoxetine for 10 min significantly inhibited OCR by 54% to 1.6 6 0.3 pmol O 2 islet À1 min À1 (p < .01; ANOVA, Sidaks's multiple comparison test); a magnitude of block larger than that observed for MIN6 cells at the same drug concentration (33%; Unpaired t-test with Welch's correction) data which suggests an IC 50 of $100 mM for fluoxetine in the intact islet. To explore candidate target sites for the acute effect of fluoxetine on beta-cell metabolism, a range of substrates which feed in at different entry points of the catabolic pathway for glucose, stimulate OCR and elicit insulin secretion (Daunt et al., 2006) were tested for their susceptibility to inhibition by this SSRI. These were D-glyceralydehyde, methylpyruvate, and a-ketoisocaproate (all at 10 mM), and the electron shuttle TMPD/ascorbate (ASB) (Duchen et al., 1993) . Of these, only glyceraldehyde did not stimulate OCR relative to the osmotic control, 10 mM 3-O-methyl glucose, (MOG; Figure 5A ; Kruskal-Wallis, Dunn's multiple comparison test). Within 10 min of incubation, 30 lM fluoxetine inhibited respiration in the presence of all these substrates, except MOG where the block failed to reach significance, an effect size regardless of the substrates' ability to stimulate OCR ( Figure 5B ; Mann-Whitney test relative to respective vehicle control in each substrate). Although the magnitude of block produced by fluoxetine was unrelated to the change in OCR produced by substrate, it was positively correlated with the magnitude of basal OCR (Spearman r, Figure 5C ). This is exemplified in Figure 5D , with the greatest inhibition produced by 30 lM fluoxetine was in cell suspensions with the largest basal OCR (Spearman r ¼ 0.64, p < .0001). This phenomenon was further explored with different glucose concentrations ( Figure 5E and F) . Figure 5E illustrates that a significant decrease in OCR occurred with fluoxetine (76% 6 2.6%; p < .001 for all cases, paired Student's ttest); an effect independent of glucose concentration and the OCR stimulated by the sugar (Spearman r ¼ 0.04, p $ .5). Because the magnitude of the SSRI effect is independent of glucose concentration, when the effect of the drug is plotted as a % of the OCR measured in glucose, the inhibitory effect of the AD appears to be negatively correlated with the concentration of sugar ( Figure 5F ; Spearman r ¼ À0.96, p < .01); with the SSRI appearing apparently less efficacious at the larger rates of respiration associated with higher glucose concentrations. Figure 6 demonstrates that 10 mM glucose increased lactate production commensurate with an increase in OCR. Subsequent inhibition of OCR with 30 mM fluoxetine was associated with an increment in lactate output ( Figure 6A and B) . The ability of fluoxetine to block OCR and stimulate lactate output was mimicked by 1 mM rotenone ( Figure 6C and D), with OCR blocked beyond basal in some cases. Fluoxetine at 30 mM also inhibited OCR and simulated lactate output in the human beta-cell line, 1.1B4 ( Figure 6E and F) . These effects were significantly larger than those seen in MIN6 cells. Figure 7A shows that in the absence of exogenous substrate the mitochondrial membrane potential, DWmit, as indicated by Rh123 fluorescence, was stable. Within one minute of 10 mM glucose addition, a sustained decrease in fluorescence occurred; an effect consistent with energization of the mitochondria and polarization of DWmit associated with enhanced mitochondrial electron transport due to glucose metabolism (Duchen et al., 1993) . Application of 2.5 lg ml À1 oligomycin decreased fluorescence consistent with an increase in DWmit due to the block of H þ leakage through the F O -F 1 -ATPase (Duchen et al., 1993) .
PAR
Subsequent addition of 1 lM antimycin increased Rh123 fluorescence; an observation consistent with the abolition of mitochondrial electron transport and collapse of DWmit since subsequent addition of 1 lM of the mitochondrial protonophore FCCP did not elicit a further increase in fluorescence ( Figure 7A ). Figure 7B shows that after energization of DWmit with glucose, 30 lM fluoxetine increased Rh123 fluorescence; however, the depolarization of DWmit produced by fluoxetine was incomplete as demonstrated by the collapse of DWmit that occurred on the addition of 1 lM FCCP. Addition of 1 lM rotenone, like antimycin A, depolarized DWmit, and prevented further dissipation of DWmit by 30 lM fluoxetine and 1 lM FCCP ( Figure 7C ). H 2 O, the vehicle for fluoxetine, did not affect Rh123 fluorescence, whereas 1 lM FCCP could still collapse DWmit ( Figure 7D ). Since the absolute value of DWmit reflects a balance between its generation by electron transport and its dissipation, predominantly via F O -F 1 -ATPase activity (Duchen et al., 1993) , the ability of an agent to depolarize DWmit can be due to either inhibition of its generation or/and potentiation of its dissipation. On the basis of the retained ability of fluoxetine to inhibit OCR in the presence of FCCP, we assumed the former and quantified the action of fluoxetine on DWmit by its initial rate of effect (DRh123; Figure 7E ). DRh123 was positively associated with drug concentration (Pearson r ¼ 0.972, p < .01), with 10 lM the lowest fluoxetine concentration deemed to have a significant effect (ANOVA, Dunnett's post comparison test). Although 30 lM fluoxetine depolarized DWmit relative to H 2 O, the vehicle control (p < .01, Kruskal-Wallis Dunn's multiple comparison test), the magnitude of this effect was unrelated to the extent by which glucose energized DWmit (Pearson p > .3), nor did it reverse the effect of glucose on DWmit ( Figure 7F) . Figure 8 shows that 1 mM Antimycin A after 30 min, but not acutely applied 30 mM fluoxetine after 120 min, significantly increased ROS in MIN6 cells relative to vehicle control (DMSO; p < .001, ANOVA Holm-Sidak). F, Glucose concentration-response relationships for the % inhibition of OCR by 100 mM fluoxetine. Data are means 6 SD and are calculated from that shown E.
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FCCP, but Not Fluoxetine Reactivates K ATP Channel Activity Figure 9A shows that in the absence of glucose, cell-attached patches displayed single-channel currents with biophysical metrics characteristic for K ATP -channels: a single channel current amplitude (i) of 4.86 0.1 pA, burst kinetics and a mean openchannel dwell time of 2.2 6 0.1 ms (n ¼ 27-37; Ashcroft et al., 1988; Smith et al., 2001) . Figure 9A and B shows that addition of 10 mM glucose significantly reduced NPo by 99% (42-0%, 95% C.I; p < .0001; Wilcoxon Signed rank test, n ¼ 46) relative to the perifusion control that was without effect (Wilcoxon Signed rank test, n ¼ 10). Fluoxetine (1-100 mM) failed to reactivate K ATP channel activity blocked by glucose, even after 10 min the longest period tested ( Figure 9A and C) . Although 1 mM rotenone, a mitochondrial toxin which mimics the metabolic effects of fluoxetine, nor 1 mM antimycin also failed to reactivate the channel, 100 nM FCCP did (Kruskal-Wallis; Figure 9A and C) confirmed by the subsequent abolition of activity with 20 mM tolbutamide, a potent selective inhibitor of this channel type (Smith et al., 2001) .
DISCUSSION
Antidepressants Are Cytotoxic to MIN6
Since all 3 ADs decreased MTT reduction and ATP levels, effects with similar IC 50 s without affecting cell density, suggests these ADs act to impair redox status. Previous studies have demonstrated that fluoxetine (Caminada et al., 2006; Krishnan et al., 2008; Levkovitz et al., 2005) , clomipramine (Abdel-Razaq et al., 2011; Levkovitz et al., 2005) , and paroxetine (Amit et al. 2009 ) inhibit cell metabolism with IC 50 values similar to those we report. Although these IC 50 's exceed therapeutic concentrations, all 3 drugs produced cytotoxic effects at the therapeutically relevant concentration of 100 nM. Despite intra-islet concentrations for these drugs being unavailable, magnetic resonance spectroscopy of 19 F fluoxetine in the human brain has revealed a 10-to 20-fold accumulation of fluoxetine ($13 mM) relative to plasma after 6-12 months treatment (Karson et al., 1993; Bolo et al., 2000) , Together, these findings help explain the diabetogenic risk associated with prolonged AD usage and exposure (Andersohn et al., 2009; Brown et al., 2008; Derijks et al., 2008; Khoza and Barner, 2011; Kivim€ aki et al., 2010; Lustman et al., 1997; Rubin et al., 2008) .
AD Effects Are Not Mediated by Blockade of Serotonin Transport
Fluoxetine and paroxetine are SSRIs, whereas clomipramine acts as an SSRI and a noradrenaline re-uptake inhibitor. These drugs are thought to achieve their antidepressant therapeutic activity, in part, through blockade of the serotonin transporter (SERT) which enhances serotonin (5-HT) concentrations in the brain to alleviate the symptoms of depression (Blier and El Mansari, 2013) . Pancreatic b-cells secrete 5-HT which may exert autocrine effects (Bennet et al., 2015) . However, an involvement of SERT for the cytotoxic effects of these ADs can be dismissed, since b-cells do not express the Slc64a gene that encodes for SERT nor do ADs affect the release of 5-HT from them (Cataldo et al., 2015) .
Antidepressants Impair b-Cell Mitochondrial Function
The IC 50 for the inhibition of oxidative respiration by acute application of fluoxetine on intact b-cells is comparable to that (Curti et al., 1999; Souza et al., 1994) and the voltage-dependent anion channel, VDAC (Nahon et al., 2005) . However, neither of these proteins are likely targets here since when the activity of F 0 F l -ATPAse was uncoupled from mitochondrial electron transport by FCCP, the IC 50 for fluoxetine was not increased; whereas blockade of VDAC by fluoxetine is associated with an enhanced, not impaired, mitochondrial function (Nahon et al., 2005) . The fact that the acute IC 50 values exceeded the chronic values ones probably reflect a failure of the ADs to reach equilibrium over the short time periods employed. This is exemplified by fluoxetine whose affinity increased with incubation time with a half-life of 6.9 h.
The observations that the chronic AD bioenergetic effects were not associated with changes in cell density is consistent with a decrease in cell oxidative respiration capacity; an idea supported by the loss of mitochondrial Complexes seen in other systems: 30% decrease in Complex IV in the b-cell line INS1E with 48-h exposure to 1 mM fluoxetine (De Long et al., 2014) ; >20% decrease for all 4 Complexes in CHO cells after 18-h incubation with >10 mM clomipramine (Abdel-Razaq et al., 2011) . Moreover, at 1 mM, the atypical AD bupropion, an AD associated with an increased risk of diabetes (Andersohn et al., 2009) , impairs mitochondrial Complex IV function and insulin secretion in INS1E cells after 48 hour exposure (Woynillowicz et al., 2012) . Complex I and complex III inhibition is considered the main source of ROS in cells (Chen et al., 2003 ; Je zek and Hlavat a, 2005). Such a process was demonstrated in our chronic but not acute studies, an effect previously observed in INS1E cells when incubated with fluoxetine (De Long et al., 2014) . These data suggest that maintained loss of mitochondrial Complex activity and ROS production only occurs with prolonged AD exposure; effects similar to those observed in b-cells with exogenous H 2 O 2 (Li et al., 2009 ).
Fluoxetine Blocks b-Cell Lipid Metabolism
In the absence of exogenous substrate pancreatic b-cells respire primarily via beta-oxidation of endogenous lipids (Corkey et al., 1989) which involves FADH and Complex II/III. The observation that acute fluoxetine had an effect size correlated with basal, rather than stimulated, respiration lends support to Complex II/ III as an acute target for this AD; since inhibition of Complex II/ III will prevent beta-oxidation of endogenous lipids and OCR. Indeed, fluoxetine mimics the antimycin inhibition of Complex II/III on DWmit. A mitochondrial target for fluoxetine is supported by the increase in lactate production that occurs with this SSRI, a phenomenon, like that produced by rotenone, explained by a failure of the beta-cell to oxidize NADH via Complex I which necessitates NADH recycling via increased lactate generation from pyruvate. An event that helps maintains cytosolic ATP and K ATP channel block.
Antidepressants Decrease Insulin Secretion by MIN6
The decrease in glucose-stimulated insulin secretion may be due to a combination of both oxidative stress and decreased ATP production. Pancreatic b-cells are characterized by a relatively weak expression of superoxide dismutase, catalase and glutathione peroxidase (Grankvist et al., 1981; Lenzen et al., 1996) ; enzymes that metabolize and neutralize ROS. Consequently, exposure to oxidative stress as is the case here, may be sufficient to impair glucose-stimulated insulin secretion (Li et al., 2009; Maechler et al., 1999; Sakai et al., 2003) . The finding that co-incubation with GSH partially reversed the ability of AD to inhibit MTT reduction is consistent with this notion. The associated suppression of intracellular ATP due to bioenergetic disruption will also act to decrease insulin secretion as it is the major coupling factor for glucose-induced insulin secretion (Eliasson et al., 1997; Smith et al., 1989) and help explains their ability to induce hyperglycemia without hyperinsulinemia in vivo (Gomez et al., 2001; Yamada et al., 1999) .
Fluoxetine Fails to Activate K ATP Channels in MIN6 Plasma-membrane K ATP channel activity was blocked by glucose and solely reactivated by FCCP; however, they were not reactivated by fluoxetine, rotenone or antimycin. This is because these compounds failed to impair mitochondrial ATP production sufficiently to reactivate K ATP ; unlike FCCP which uncouples respiration and leads to cellular consumption of ATP via reverse mode F 0 F 1 -ATPase activity (Rustenbeck et al., 1997) . Rotenone and antimycin are well-known to inhibit insulin secretion independently of K ATP channels due to the intimate relationship between mitochondrial metabolism and secretory steps distal to membrane ionic events (MacDonald and Fahien, 1990 ; Orts€ ater et al., 2002), and as we show here fluoxetine, too can also impair mitochondrial respiration acutely which explains its acute hyperglycemic affects in vitro (Antoine et al., 2004; Cataldo et al., 2015) and in vivo (Gomez et al., 2001; Yamada et al., 1999) ; effects meditated by the energetic requirements of distal events in secretion such as Ca 2þ entry (Smith et al., 1989) and exocytosis (Eliasson et al., 1997) .
Suitability of MIN6 as a Metabolic Model of Native Pancreatic Beta-Cells
We found that glucose stimulated MIN6 OCR 1.4-fold that of basal, close to that of 1.6 observed for mouse islets. Furthermore, the MIN6 cell OCR of 1.7 nmol 10 6 cells À1 min À1 in glucose is similar to that of 3 nmol O 2 10 6 cells À1 min À1 in mouse islets (Daunt et al., 2006) . Moreover, the 2.6 nmol min À1 10 6 cell lactate from MIN6 in 10 mM glucose is similar to that for rat islets: 2.0 nmol min À1 10 6 cell (Sener et al., 1976) . Furthermore, we estimate a lactate to OCR ratio of 3.6 6 1 (n ¼ 8) in MIN6, similar to that reported for rat b-cells (2.4; Sener et al., 1976) . Together, these data support MIN6 cells as a suitable metabolic model of native b-cells in which to study mitochondrial function.
CONCLUSION AND CLINICAL IMPLICATIONS
We found that paroxetine, clomipramine and fluoxetine were cytotoxic to mouse pancreatic b-cells, an effect dependent on concentration and exposure duration. Two effects were determined: an immediate direct block of mitochondrial Complex activity followed by a longer term loss of Complex activity associated with increased ROS. Importantly, adverse metabolic effects were seen at chronic AD concentrations of 100 nM; a value less than the median therapeutic concentration for most dosage regimens (Reis et al., 2009) . Moreover, as the plasma concentration for these ADs are well established to be related to dose (Reis et al., 2009 ), a daily fluoxetine dose of 80 mg which can yield steady state plasma concentrations >2 mM (Lundmark et al., 2001 ) is a concentration sufficient to disrupt beta-cell mitochondrial bioenergetics. Indeed, plasma concentrations during loading and drug-drug interactions concentrations may surpass 2 mM. Why these ADs seem to have adverse clinical affects manifested predominantly by pancreatic b-cell dysfunction probably relates to the poor antioxidant abilities of this cell type, since they were mitigated in part by GSH. Overall, our data suggests that a direct cytotoxic effect of these ADs on pancreatic b-cells may contribute to the diabetogenic potential of antidepressants.
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